Abstract The Effects of Cyclophosphamide on Apoptosis in Chronic Myeloid Leukemia K-562 Cell Lines Aim: In this study, we aimed to investigate apoptotic effects of cyclophosphamide, which is widely used in the treatment of numerous cancer types, on K-562 cell line, human chronic myeloid leukemia cells, in association with caspase 8. Method: In experiment groups to indicate cytotoxicity, spesific dose of cyclophosphamide for a certain time period was applied and analyzed by Tyripan Blue Exclusion test. After 24 and 48 hours, in experiment groups we carried out RNA isolation with E.Z.N.A total RNA kit and cDNA with first strand cDNA kit. Caspase-8 and housekeeping (glyceraldehydephosphate dehydrogenates GAPDH) gene expression levels were determined by Real-Time online revers transkriptaz RT-PCR. Crossing point (CP) in each groups compared GAPDH and determined expression relative rate (Efficiency). Primary and secondary apoptotic cell portions were determined by Annexin-V FITC kit with flow cytometry. Results: In K-562 cell lines, at the 24th hour the significant increase in caspase-8 expression level in cyclophosphamide 10-7 M and 10-6 M groups when compared with the negative control. At the 48th hour, increase in all groups were seen, but only 10-6 M group was significantly increased. Conclusion: This study indicates that cyclophosphamide is inducing apoptosis.
Türkçe Özet:Amaç: Bu çalışmada, insan kronik myeloid lösemi K–562 hücre hattında, çeşitli kanser türlerinde yaygın olarak kullanılan siklofosfamidin, kaspaz-8 ile ilişkili olarak apoptoz üzerindeki etkilerinin araştırılması amaçlandı. Yöntem: Deneysel gruplarda sitotoksisiteyi göstermek için belirli dozlarda siklofosfamid uygulandı ve tripan mavisi canlılık testi ile analiz edildi. Deney gruplarında 24. ve 48. Saat sonra E.Z.N.A. total RNA kiti ile RNA ve first strand cDNA kiti ile cDNA elde edildi. Kaspaz–8 ve gliseraldehidfosfat dehidrogenaz gen ekspresyonları, Real–Time online Revers Transkriptaz Real–Time PCR yöntemi ile belirlendi. Her grubun geçiş noktası değeri, gliseraldehidfosfat dehidrogenaz ile karşılaştırıldı ve ekspresyonların rölatif oranı saptandı. Erken ve geç apoptotik hücre sayıları Annexin–V FITC kiti ile akım sitometrede gösterildi. Bulgular: K–562 hücre hattında, 24. saatte siklofosfamitin 10-7 M ve 10-6 M gruplarında, kaspaz–8 geni için negatif kontrole göre kıyaslandığında ekspresyon düzeylerinde anlamlı bir artış saptandı. 48. saatte tüm gruplarda artış olmasına karşın, siklofosfamitin 10-6 M grubunda bu artış anlamlı bulunmuştur. Sonuç: Bu çalışma, siklofosfamitin apoptozu indüklediğini göstermektedir.
Primary Language | Turkish |
---|---|
Journal Section | Articles |
Authors | |
Publication Date | June 1, 2008 |
Submission Date | June 13, 2014 |
Published in Issue | Year 2008 Volume: 1 Issue: 2 |
MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.
Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.
Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.
Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.
Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.
Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.
This work is licensed with Attribution-NonCommercial 4.0 International.